Merck & Co., Inc. (MRK) receives a strong valuation ranking of 61 from InvestorsObserver's data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. MRK has a better value than 61% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
MRK has a trailing twelve month Price to Earnings (PE) ratio of 26.8. The historical average of roughly 15 shows a poor value for MRK stock as investors are paying higher share prices relative to the company's earnings. MRK's high trailing PE ratio shows that the firm has been trading above its fair market value recently. Its trailing 12-month earnings per share (EPS) of 2.76 does not justify the stock's current price. However, trailing PE ratios do not factor in the company's projected growth rate, resulting in many newer firms having high PE ratios due to high growth potential enticing investors despite inadequate earnings.
MRK currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 1.84. The market is currently overvaluing MRK in relation to its projected growth due to the PEG ratio being above the fair market value of 1. MRK's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
MRK' has a weak valuation at its current share price on account of a overvalued PEG ratio despite strong growth. MRK's PE and PEG are worse than the market average leading to a below average valuation score.